| Authors: |
Newman AB; Brigham and Women's Hospital, Boston, MA, USA., Martin AR; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hughes ME; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Higgins A; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Kirkner GJ; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Files J; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Skeffington M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Moore M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Strauss S; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Kuhnly N; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Crowley L; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Lin NU; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Freedman RA; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: rachel_freedman@dfci.harvard.edu. |
